Brands
Kwality Wall’s twister pops into India’s summer heat
MUMBAI: Kwality Wall’s, has introduced its global brand, Twister, to the Indian market, offering a unique three-layered ice lolly designed to combat the summer heat.
Twister, a popular Unilever brand enjoyed in over 25 countries, arrives in India with two new flavours, Twister Mango, featuring mango and vanilla swirls around a strawberry core, and Twister Pineapple, combining pineapple and lemon swirls with a strawberry core.
Targeted at young Indian consumers seeking a novel refreshment, Twister boasts real fruit juice and a multi-layered design, delivering a burst of flavour in each serving, with less than 65 calories per lolly.
To enhance the summer launch, Kwality Wall’s is running a national promotion, giving away ‘30 Lakh Free Ice Candies’, redeemable at over 100,000 stores across India. A supporting multi-media campaign and promotional film will also be released.
HUL head of ice cream business Toloy Tanridagli stated, “We are thrilled to bring one of our iconic global brands, Twister to India in two exciting and refreshing flavours. Refreshments are a huge category, over 6.6 billion Euros and consumers are seeking new and exciting refreshments options during hot Indian summers. As a top-selling brand in the Unilever portfolio and a global favourite, our goal in India is to offer a delightful treat that resonates with young consumers and adds a fun twist to their summer. Our unique summer promotion will undoubtedly elevate the experience for Indians.”
DDB Mudra group chief creative officer & executive director Rahul Mathew added, “With Kwality Wall’s Twister, we wanted to capture the essence of refreshing indulgence and joy. The ad is a celebration of spontaneous fun the kind that makes you forget everything else and just savor the moment. The swirling visuals and vibrant energy mirror the irresistible twist of flavors, making it an experience that’s as playful as it is delicious.”
The launch of Twister in India represents a significant step for Kwality Wall’s, aiming to establish the product as a summer staple.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
